Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Public Law 92-463 (5 U.S.C. app. 2)).
Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.
|Name of committee||Date of expiration|
|Science Board to the Food and Drug Administration||June 26, 2004|
|Allergenic Products Advisory Committee||July 9, 2004|
|Cardiovascular Drugs Advisory Committee||August 27, 2004|
|Endocrinologic and Metabolic Drugs Advisory Committee||August 27, 2004|
|Oncologic Drugs Advisory Committee||September 1, 2004|
|Anti-Infective Drugs Advisory Committee||October 7, 2004|
|Dermatologic and Ophthalmic Drugs Advisory Committee||October 7, 2004|
|Biological Response Modifiers Advisory Committee||October 28, 2004|
|Technical Electronic Product Radiation Safety Standards Committee||December 24, 2004|
|Antiviral Drugs Advisory Committee||February 15, 2005|
FOR FURTHER INFORMATION CONTACT:
Linda A. Sherman, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.End Further Info Start Signature
Dated: March 10, 2003.
Linda Arey Skladany,
Associate Commissioner for External Relations.
[FR Doc. 03-6397 Filed 3-17-03; 8:45 am]
BILLING CODE 4160-01-S